Last reviewed · How we verify
NCT00594672
Age-Related Eye Disease Study (AREDS) Follow-Up
trial in Age-Related Macular Degeneration in 110 participants. Participants enrolled and being followed up; not accepting new ones.
Quick facts
| Lead sponsor | National Eye Institute (NEI) |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 2 June 2008 |
| Sites | 1 location across United States |
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
- Cataract — all drugs for Cataract →
Sponsor
National Eye Institute (NEI)
Who can join
Adults 50 to 100, any sex, with Age-Related Macular Degeneration or Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts. Participants in the former AREDS protocol are eligible for this study. Participants have a complete eye examination once a year and are contacted at least once a year between visits to check on their status. The eye examination includes measurement of visual acuity (vision chart test) and examination of the inside of the eye after the pupils have been dilated with eye drops. Photographs of the inside of the eye may be taken using a special camera that flashes a bright light in the eye. A blood sample may be obtained to test for cholesterol level and genes related to inflammation.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study.
Sangiovanni JP, Agrón E, Meleth AD, Reed GF, et al · · 2009 · cited 122× · PMID 19812176 · DOI 10.3945/ajcn.2009.27594 -
Adherence to a Mediterranean diet, genetic susceptibility, and progression to advanced macular degeneration: a prospective cohort study.
Merle BM, Silver RE, Rosner B, Seddon JM. · · 2015 · cited 103× · PMID 26490493 · DOI 10.3945/ajcn.115.111047 -
Validated Prediction Models for Macular Degeneration Progression and Predictors of Visual Acuity Loss Identify High-Risk Individuals.
Seddon JM, Rosner B. · · 2019 · cited 45× · PMID 30389371 · DOI 10.1016/j.ajo.2018.10.022 -
Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis.
Seddon JM, Silver RE, Rosner B. · · 2016 · cited 41× · PMID 27471039 · DOI 10.1136/bjophthalmol-2016-308624 -
Dietary folate, B vitamins, genetic susceptibility and progression to advanced nonexudative age-related macular degeneration with geographic atrophy: a prospective cohort study.
Merle BM, Silver RE, Rosner B, Seddon JM. · · 2016 · cited 36× · PMID 26961928 · DOI 10.3945/ajcn.115.117606 -
Family History of Age-Related Macular Degeneration and Genetics Predict Progression to Advanced Age-Related Macular Degeneration Adjusting for Macular Status, Demographic, and Lifestyle Factors.
Seddon JM, De D, Rosner B. · · 2023 · cited 8× · PMID 37437830 · DOI 10.1016/j.ajo.2023.06.017 -
The role of nutritional factors in transitioning between early, mid, and late stages of age-related macular degeneration: prospective longitudinal analysis.
Seddon JM, De D, Rosner B. · · 2024 · cited 7× · PMID 39181206 · DOI 10.1016/j.ajcnut.2024.08.019
Verify or expand the search:
- PubMed search for NCT00594672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
- NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
- NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease · Phase 1 · recruiting
- NCT04833361 — Potential Environmental Causes of Uveal Coloboma · completed
- NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss · NA · active not recruiting
- NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00594672 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00594672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing